Evaluating the Efficacy of FoundationDRS Solo in Addition to Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSamaritan Biologics

About this trial

The goal of this clinical trial is to learn if using FoundationDRS Solo improves healing of chronic, non-healing foot ulcers in diabetic patients.

The main question that this study aims to answer is:

Does FoundationDRS Solo, when used in conjunction with standard of care wound management techniques, result in a higher percentage of target ulcers achieving complete closure (i.e. healing) as compared to ulcers being treated with standard of care alone after 12 weeks of treatment.

One ulcer on each participant's foot will receive weekly applications of 1) FoundationDRS Solo and standard of care wound management or 2) standard of care wound management alone. Pictures of the ulcer and measurements of its size will be measured every week to track its healing progress over a total treatment period of 12 weeks. Additionally, the participants will be asked to fill out a questionnaire about the wound impacts their life and their quality of life.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

1. Subjects must be at least 18 years of age or older.

Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus requiring treatment with oral medications and/or insulin replacement therapy.

At randomization subjects must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 20.0 cm2 measured post debridement prior to randomization at treatment visit 1 (TV1).

The target ulcer must have been present for a minimum of 4 weeks and is unresponsive (defined by less than 50% wound area reduction) to standard wound care.

Disqualifiers

The index ulcer has been offloaded with protocol defined offloading device for at least 14 days prior to randomization (i.e. Screening through TV1/Randomization).

The potential subject must consent to using the prescribed offloading method for the duration of the study.

The potential subject must agree to attend the weekly study visits required by the protocol.

The potential subject must be willing and able to participate in the informed consent process.

Trial design

Design model

Parallel

Treatments tested in this trial

  • FoundationDRS Solo

    Other intervention

    FoundationDRS Solo is a porous, degradable composite scaffold composed of chitosan and chondroitin sulfate

  • Standard of Care

    Other intervention

    Standard of care (SOC) will include cleansing of the index wound with sterile normal saline solution, followed by sharp debridement to remove necrotic tissue, application of appropriate dressings and wound off-loading

Treatment groups

124 Participants
are divided into 2 treatment groups
Group A: FoundationDRS SoloExperimental treatment 2 interventions
Group B: Standard of CareActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Incidence of Complete Wound Closure

The percentage of wounds completely healed. Complete healing will be defined as 100% epithelialization without drainage and need for dressing or wound size ≤ 0.1cm\^2 as determined by the site investigator and validated by a blinded review board.

Time frame
12-weeks following study screening phase

Secondary outcomes

1

Time to wound closure

Time to wound closure over 12 weeks will be determined via a Kaplan-Meier analysis

Time frame
12-weeks following study screening phase
2

Percent reduction in wound area

Percent reduction of wound area \[(Ai-Axw\]) / Ai\] x100, where Ai is the area of the index wound at randomization, Axw is the wound area at weekly intervals.

Time frame
12-weeks following study screening phase
3

Adverse Events

A symptom, sign, illness or experience that develops or worsens in severity during the course of the study. Intercurrent illnesses or injuries will be regarded as adverse events. Abnormal results of laboratory or diagnostic procedures are considered to be adverse events if the abnormality: Leads to study withdrawal. Is associated with a serious adverse event. Is associated with clinical signs or symptoms. Leads to additional treatment or to further diagnostic tests. Is considered by the Investigator to be of clinical significance

Time frame
12-weeks following study screening phase
4

Wound Quality of life (Wound-QoL) questionnaire

Average scores will range from 0 (lowest score) to 4 (highest score), with a higher score indicating that the wound effected the subject's quality of life more severely.

Time frame
12-weeks following study screening phase

Other outcomes

1

Proportion of ulcers that completely heal in patients 65 years or older

Proportion of ulcers that completely heal in patients 65 years or older for CAMP plus SOC versus SOC alone

Time frame
12-weeks following study screening phase

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Samaritan Biologics

Lead sponsor

Emergent Clinical Consulting, LLC

Collaborator

This trial is not recruiting at the moment. You can still explore other options: